Newport Biotech Consultants

Dr. John Morrow and Dr. Kaspar Hoebe discuss research at Cincinnati Children's Hospital

Dr. Chris Mayhew and technician Amy Pitstick of Cincinnati Children's Hospital

John Morrow and Matt Gaevert discuss Kiyatec's 3D culture technology

Morrow and Mayhew consider stem cell technology at Cincinnati Children's

A visit to Biologic Covington KY

Morrow discussing Bexion technology with Dr. Neil Chaudhary

Discussing protein characterization assays at Bexion

Morrow meets with Paul Davis, CEO Quanta Biodesign

with Steve King, CEO Peregrine Pharmaceuticals

with Cheng Liu, CEO Eureka Pharma

Performance exceeding expectations.

Newport Biotechnology Consultants serves the life sciences industry providing research, writing, business planning and emergency management solutions.  Founder Dr. K. John Morrow Jr. (President/CEO) draws upon academic and industrial experience to cover new developments and technologies in antibody therapeutics and related areas of biotechnology. With an extensive list of publications in trade and peer-reviewed journals, we are prepared to evaluate business plans, prepare technical reports and develop advertising literature. To download some of my latest publications go to "Who We Are" page.

Published 2014

A range of quality services

  • Writing expertise
    • life sciences industry
    • specialization in molecular immunology
  • Coverage of new developments and technologies
  • Emergency management
  • Bio-Safety Consulting
  • Business plan evaluation.
  • Translation, Interpretation   (English/Italian) 
  • Recently published: "Cancer, Autism and Their Epigenetic Roots" McFarland Publishers

View all Services

Recent Blog Entries

dramatic decreases in  the cost of genome sequencing

Industrial Scale Genome Sequencing to Uncover Multifactorial Diseases

January 29, 2016

In my book on epigenetics, I discussed the problems of investigating diseases with a multifactorial basis, that is, conditions in which many genes determine a condition, such as cardiovascular disease. I argued that because a thousand or more genes may be involved, and each makes a small contribu...

Read More
*